Phenytoin was synthesized in 1908. Merritt and Putnam,1 in 1938, described its anticonvulsive properties, and it was this article that began the drug's popularity as a cornerstone of anticonvulsive therapy.1 We report our experience in an open trial with the use of phenytoin in the treatment of patients with discoid lupus erythematosus (DLE) at the Dermatological Institute of Jalisco (Mexico).
Materials and Methods.
The age, sex, onset of disease, activity, time, length, extent, and distribution of the lesions as well as previous treatments were recorded in all patients. Ninety-three patients (76 women and 17 men) were included in this study. All patients had clinically and histologically confirmed DLE. Routine blood analyses were performed in all subjects. Patients with systemic lupus erythematosus were excluded. The treatment consisted exclusively of 100 mg of sodium diphenylhydantoin administered orally three times daily. Informed consent was obtained from each patient.In all patients, cutaneous lesions were examined
Rodriguez-Castellanos MA, Rubio JB, Gómez JFB, Mendoza AG. Phenytoin in the Treatment of Discoid Lupus Erythematosus. Arch Dermatol. 1995;131(5):620-621. doi:10.1001/archderm.1995.01690170124029